Are Biotech Funds Buys Once Again?
While a number of market industries were fearful of a Trump Presidency, nowhere was the concern more prevalent than in the biotech and drug segment. After all, Trump came out several times against the pricing practices in the drug market, vowing to do something to make this a more affordable area…. (Read full article at Zacks.)